Trovafoxacin: a novel extended spectrum quinolone

Edited by
Sebastian G. B. Amyes
University of Edinburgh, Edinburgh, UK

Frederick R. Falkiner
University of Dublin, Trinity College, Dublin, Ireland

Mark H. Wilcox
University of Leeds, Leeds, UK

Martin J. Wood
Birmingham Heartlands Hospital Trust, Birmingham, UK

Assisted by
Philip J. Daly
BSAC, Birmingham, UK

This supplement was sponsored by Pfizer (USA) Inc.

Material published in this supplement has been peer-reviewed by an independent editorial team appointed by the Editor-in-Chief of the Journal in accordance with the guidelines published in the Advice to contributors and editorial statements published previously (Volume 19 (1987), pp. 711–2 and Volume 25 (1990), pp. 731–2).
## Contents

Preface iii

The chemistry and biological profile of trovafloxacin
*K. E. Brighty and T. D. Gootz* 1

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer
*K. V. I. Rolston, D. H. Ho, B. LeBlanc, H. Streeter and T. Dvorak* 15

Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes
*S. K. Spangler, M. R. Jacobs and P. C. Appelbaum* 23

Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates
*B. A. Cunha, S. M. Hussain Qadri, Y. Ueno, E. A. Walters and P. Domenico* 29

In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates

In-vitro and in-vivo activity of trovafloxacin against *Streptococcus pneumoniae*
*K. P. Klugman and T. D. Gootz* 51

The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria
*A. M. Sefton, J. P. Maskell, A. M. Rafay, A. Whiley and J. D. Williams* 57

Susceptibility of *Chlamydia trachomatis* to trovafloxacin
*R. B. Jones, B. Van Der Pol and R. B. Johnson* 63

A study of the phototoxic potential of trovafloxacin in BALB/c mice

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin
*J. Vincent, J. Venitz, R. Teng, B. A. Baris, S. A, Willavize, R. J. Polzer and H. L. Friedman* 75

Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers
*J. Vincent, R. Teng, L. C. Dogolo, S. A. Willavize and H. L. Friedman* 81

Oral bioavailability of trovafloxacin with and without food in healthy volunteers
*R. Teng, L. C. Dogolo, S. A. Willavize, H. L. Friedman and J. Vincent* 87

Effect of Maalox and omeprazole on the bioavailability of trovafloxacin
*R. Teng, L. C. Dogolo, S. A. Willavize, H. L. Friedman and J. Vincent* 93